Clinical research focused on the predictive capacity of biomarkers in evaluating tumor response to immunotherapies has implicated some serum biomarkers to be prognostic factors associated with good outcomes of HCC, such as PIVKA, DCP, and VEGF46–48. Here, ACE is linked to hepatocellular carcinoma.